Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01550744 · ClinicalTrials.gov registry record · Phase 3
A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis
A Phase 3 study, sponsored by Janssen Biotech.
- Completed
- Registry status
- Phase 3
- Development phase
- 478
- Enrollment target
NCT01550744 is a Phase 3 study that has completed, run by Janssen Biotech. The registered enrollment target is 478 participants.
The verdict
NCT01550744, a Phase 3 study, has completed, sponsored by Janssen Biotech.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 478 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the effect of extending maintenance dosing intervals beyond 12 weeks on the clinical efficacy and safety of ustekinumab in subjects with moderate-to-severe plaque psoriasis.
Interventions
- DRUG Placebo
- DRUG Ustekinumab 45 mg
- DRUG Ustekinumab 90 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 478 participants |
| Start Date | 2012-03 |
| Est. Completion | 2015-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01550744
The ClinicalTrials.gov registry entry for NCT01550744 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 478 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Biotech, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01550744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01550744 about?
NCT01550744 is a clinical study titled "A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis". The purpose of the study is to assess the effect of extending maintenance dosing intervals beyond 12 weeks on the clinical efficacy and safety of ustekinumab in subjects with moderate-to-severe plaque psoriasis.
What is the current status of trial NCT01550744?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 478 participants. The study started on 2012-03. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01550744?
The interventions under investigation include: Placebo (DRUG), Ustekinumab 45 mg (DRUG), Ustekinumab 90 mg (DRUG).
Who is sponsoring clinical trial NCT01550744?
This trial is sponsored by Janssen Biotech, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.